Schedule

World Immunotherapy Council's 4^th Young Investigator Symposium

Liberty Ballroom (Marriott Marquis)
7:30 a.m.–1 p.m. EST*

7:30 a.m.

Opening Statement 
Organizer

7:45 a.m.

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
Zheng Zhu—Chinese American Hematology Oncology Network (CAHON)

8:02 a.m.

Chemokine driven spatially organized tumor immunity fosters long survival
Ziena Abdulrahman, Msc—KWF working society-Dutch Tumor Immunology Meeting (KWF-DTIM)

8:19 a.m.

RevCAR platform as a combinatorial approach for targeting acute myeloid leukemia
Liliana Loureiro —Tumor Immunology Meets Oncology (TIMO) 

9:10 a.m.

Adjuvant and neoadjuvant immunotherapy for hepatocellular carcinoma
Chiun Hsu—the Taiwanese Oncology Society (TOS) 

9:27 a.m.

Differential expression of adhesion molecules defines myeloid cell infiltration in  glioblastoma and comprises a therapeutic target
Defne Bayik—Society for Immunotherapy of Cancer (SITC) 

9:44 a.m.

CRISPR-Cas9-mediated knockout of PD-1 for tumor-infiltrating lymphocyte-based adoptive T-cell therapy
Chris Chamberlain—Scandinavian Network for Immunotherapy of Cancer (SNIC) 

10:01 a.m.

Novel model for evaluation of CD3-redirection combinatorial therapies in the context of a syngeneic tumor model with fully competent immune system
Olesya Chornoguz—Progress in Vaccination Against Cancer (PIVAC)

10:18 a.m.

The clinical utility and safety of Short-course Immune checkpoint inhibitors (ICI) in multiple tumors - A real world multicentric study from India 
George Abraham— Immuno-Oncology Society of India (I-OSI) 

10:35 a.m.

Break

10:45 a.m.

JUPITER-06: a randomized, double-blind phase III trial of toripalimab in combination with paclitaxel plus cisplatin for advanced or metastatic ESCC 
Feng Wang— Chinese Society for Clinical Oncology (CSCO) 

11:02 a.m.

Trajectory analysis of single cell RNAseq identifies factors involved in immune escape in squamous cell cancers 
Quah Hong Sheng—Singapore Society of Oncology - Cancer Immunotherapy Consortium (SSO-CIC) 

11:19 a.m.

Combination of NKT cell immunotherapy and oncolytic vesicular stomatitis virus expressing FAST proteins clears metastatic triple negative breast cancer
Adam Nelson—Canadian Cancer Immunotherapy Consortium (CCIC) 

11:36 a.m.

Insights into PD-1 blockade: how the Fc region can modulate the therapeutic activity of monoclonal antibodies targeting PD-1
Julia Moreno-Vicente—Spanish Group of Immuno-Biological Therapeutics in Cancer (GETICA) 

11:53 a.m.

Evaluation on tumor selectivity of immune response driven by STA551, an anti-CD137 agonist antibody activated in the presence of extracellular ATP
Ryo Uchikawa— Japanese Association of Cancer Immunology (JACI) 

12:10 p.m.

The effects of short chain fatty acids on the phenotype and function of human dendritic cells matured with Toll like receptor ligands
Katarzyna Piadel — Institute for Cancer Vaccines and Immunotherapy (ICVI) 

12:27 p.m.

Identification of genes and pathways associated with immune modulatory properties of biglycan in colorectal cancer cells
Karthikeyan Subbarayan – German Society for Immunology (DGfl) 

12:45 p.m.

Closing Statement 
Organizer 

Noon–1:30 p.m. EST

Meet-the-Expert Lunch

6:30–8:30 p.m. EST

Session 1
6:30–7:30 p.m. EST

6:30 p.m.



6:50 p.m.






7:00 p.m.



7:20 p.m.






Session 2
7:30–8:30 p.m. EST

7:30 p.m.



7:45 p.m.








8:15 p.m.

Grant Writing Workshop
Capitol/Congress Room (Marriott Marquis)

Moderator: Ravi Patel, MD, PhD – University of Pittsburgh

Overview of Grant Opportunities
(View On-demand)
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center

Q&A
(View On-demand)
Thomas F. Gajewski, MD, PhD – University of Chicago
Elizabeth Hill, PhD – Medical University of South Carolina
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center
Lillian Kuo, PhD – National Cancer Institute

Principles of Grant Writing
(View On-demand)
Thomas F. Gajewski, MD, PhD – University of Chicago

Q&A
(View On-demand)
Thomas F. Gajewski, MD, PhD – University of Chicago
Elizabeth Hill, PhD – Medical University of South Carolina
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center
Lillian Kuo, PhD – National Cancer Institute


Moderator: Ravi Patel, MD, PhD – University of Pittsburgh

NCI Officer Tips and Tricks
(View On-demand)
Lillian Kuo, PhD – National Cancer Institute

Mock Study Section
(View On-demand)
Scientific Review Officer: Lillian Kuo, PhD – National Cancer Institute
Chair: Thomas F. Gajewski, MD, PhD – University of Chicago
Primary Reviewer: Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center
Secondary Reviewer: Ravi Patel, MD, PhD – University of Pittsburgh
Statistical Reviewer Elizabeth Hill, PhD – Medical University of South Carolina

Q&A
(View On-demand)
Thomas F. Gajewski, MD, PhD – University of Chicago
Elizabeth Hill, PhD – Medical University of South Carolina
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center
Lillian Kuo, PhD – National Cancer Institute

7 a.m.–8:30 p.m. EST

Poster and Exhibit Hall

Presidential Welcome & Awards Ceremony
Location:
Hall D
Chair:
Patrick Hwu, MD – Moffitt Cancer Center
7:45–8:25 a.m EST

7:45 a.m.

Presidential Welcome
(View On-demand)
Patrick Hwu, MD – Moffitt Cancer Center

7:55 a.m.

Rosenberg Scholar
(View On-demand)

8:05 a.m.

Academy of Immuno-Oncology Awards
(View On-demand)

8:15 a.m.

Team Science Award
(View On-demand)

8:20 a.m.

Lifetime Achievement
(View On-demand)

Session 100: Update Session
Location:
Hall D
Chair:
Patrick Hwu, MD – Moffitt Cancer Center
8:25–8:55 a.m. EST

8:25 a.m.

Food and Drug Administration
(View On-demand)
Adnan Jaigirdar, MD, FACS – Food and Drug Administration

8:40 a.m.

Food and Drug Administration
(View On-demand)
Marc Theoret, MD – Food and Drug Administration

8:55–9:05 a.m. EST

Break

Session 101: Keynote Address
Location:
Hall D
Chair:
Patrick Hwu, MD – Moffitt Cancer Center
9:05–9:55 a.m. EST

9:05 a.m.

Introduction
(View On-demand)
Patrick Hwu, MD – Moffitt Cancer Center

9:10 a.m. 

Neutralizing Protumor Inflammation: Lessons Learned from Preclinical Mouse Models
(View On-demand)
Lisa M. Coussens, PhD – Oregon Health & Science University

9:50 a.m.

Question and Answer
(View On-demand)
Lisa M. Coussens, PhD – Oregon Health & Science University

9:55–10:10 a.m. EST

Break

Session 102: Myeloid Cells
Location:
Hall D
Co-Chairs: 
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai
10:10 a.m.–12:10 p.m. EST

10:10 a.m.

Introduction
(View On-demand)
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

10:15 a.m.

Myeloid Cells
(View On-demand)
Shannon J. Turley, PhD – Genentech

10:35 a.m.

Trem2 in Cancer
(View On-demand)
Marco Colonna, MD – Washington University School of Medicine

10:55 a.m.

Tissue-Resident Macrophages: Fueling Early-Stage Lung Cancer
(View On-demand)
Maria Casanova-Acebes, PhD – Icahn School of Medicine at Mount Sinai

11:15 a.m.

CD40
Robert H. Vonderheide, MD, DPhil – University of Pennsylvania Perelman School of Medicine

11:35 a.m.

(676) Altered circulating myeloid states associated with anti-PD-1 resistance induce T cell paralysis in human biliary cancer
(View On-demand)
Bridget P. Keenan, MD, PhD – University of San Francisco

11:45 a.m.

(209) Genetically Engineered Myeloid Cells (GEMys) as a Platform to Enhance Antitumor Immunity
(View On-demand)
Sabina Kaczanowska, PhD – National Cancer Institute

11:55 a.m.

(664) Pulmonary priming of tumor-reactive CD8⁺ T cells by DC1 is impaired by regulatory T cells
Maria Zagorulya, BS – Massachusetts Institute of Technology

12:05 p.m.

Closing Remarks
(View On-demand)
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine

Session 103: Late-Breaking Abstract Sessions
12:10–12:40 p.m. EST
Location:
Hall D
Chair:
Margaret K. Callahan, MD, PhD – Memorial Sloan Kettering Cancer Center

 12:10 p.m.

(951) A Phase 1 first in human study of adenovirally transduced anti-HER2 CAR Macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data
(View On-demand)
Kim A. Reiss, MD – University of Pennsylvania

12:25 p.m.

(958) BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors
(View On-demand)
Andreas Mackensen, MD – University Hospital of Erlangen

12:40–2:10 p.m. EST

Lunch and Poster Viewing

Concurrent Rapid Oral Abstract Presentation Session 104: Basic Research
Location:
West Salons
Co-Chairs:
Aitziber Buque Martinez, PhD – Weill Cornell Medical College
Abigail Overacre-Delgoffe, PhD – University of Pittsburgh
12:55–1:55 p.m. EST

12:55 p.m.

(805) Clonal, activated CD8+ T cells recognizing cardiac alpha-myosin drive immune checkpoint inhibitor associated myocarditis in mice
(View On-demand)
Margaret L. Axelrod, BS – Vanderbilt University

1:03 p.m.

(700) Increasing MHC-I expression to potentiate immune checkpoint blockade therapy
(View On-demand)
Shengqing Gu, PhD – Dana-Farber Cancer Institute

1:11 p.m.

(310) T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade
(View On-demand)
Yuki Muroyama, MD, PhD – University of Pennsylvania Perelman School of Medicine

1:19 p.m.

Question and Answer
(View On-demand)

1:25 p.m.

(693) Mucosal-Associated Invariant T (MAIT) Cell Regulation Networks in Anti-Tumor Immunity
(View On-demand)
Benjamin Ruf, MD – National Institutes of Health

1:33 p.m.

(885) Targeting FPR2 as a novel approach for immunotherapy in pancreatic cancer female patients – Studies of sexual immune dimorphism in the tumor microenvironment
(View On-demand)
Dhifaf Sarhan, PhD – Karolinska Institutet

1:41 p.m.

(651) Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction
(View On-demand)
Frank Lowery III, PhD – National Cancer Institute

1:49 p.m.

Question and Answer
(View On-demand)

Concurrent Rapid Oral Abstract Presentation Session 105: Clinical
Location:
East Salons
Co-Chairs:
Allison Betof, MD, PhD – Memorial Sloan Kettering Cancer Center
Rafeh Naqash, MD – Oklahoma University
12:55–1:55 p.m. EST

12:55 p.m.

(457) KEYNOTE-495/KeyImPaCT: interime analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (NSCLC)
(View On-demand)
Martin Gutierrez, MD – Hackensack Meridian Health

1:03 p.m.

(300) Longitudinal plasma proteomic profiling of non-small cell lung cancer patients undergoing immune checkpoint blockade-based therapy
(View On-demand)
Michal Harel, PhD – Oncohost LTD

1:11 p.m.

(832) Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy
(View On-demand)
John-William Sidhom, MD, PhD – Johns Hopkins University School of Medicine

1:19 p.m.

Question and Answer
(View On-demand)

1:25 p.m.

(503) Clinical Activity of ICT01, an anti-BTN3A-Targeting, γ9δ2-Activating mAb, Alone and in Combination with Pembrolizumab in Patients with Advanced/Refractory Solid Tumors: EVICTION Trial
Martin Wermke – Uniklinikum Dresden

1:33 p.m.

(379) Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma (STS) treated with neoadjuvant immune checkpoint blockade (ICB)
(View On-demand)
Emily Z. Keung, MD, MA – The University of Texas MD Anderson Cancer Center

1:41 p.m.

(354) Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study
(View On-demand)
Vicky Makker, MD – Memorial Sloan Kettering Cancer Center

1:49 p.m.

Question and Answer
(View On-demand)

Concurrent Session 106: Exhaustion vs. stem-like TILs – TILs classification
Location:
West Salons
Co-Chairs:
Andrea Schietinger, PhD – Memorial Sloan Kettering Cancer Center
Catherine J. Wu, MD – Dana-Farber Cancer Institute
2:10–3:25 p.m. EST

2:10 p.m.

Biomarkers of Exhaustion Guide the Identification of Tumor-Reactive TIL and Peripheral Blood Lymphocytes
Alena Gros, PhD – Vall d'Hebron Institute of Oncology

2:35 p.m.

Transcriptional Strategies to Counter T Cell
(View On-demand)
Patrick G. Hogan, PhD – La Jolla Institute of Immunology

3:00 p.m.

(Re)modeling Melanoma Tumor Infiltrating Lymphocytes
Niroshana Anandasabapathy, MD, PHD – Weill Cornell Medicine

Concurrent Session 107: Re-Imagine Patient Access and Care Delivery in the Era of Digital Medicine
Location:
204ABC
Co-Chairs: 
Lynda Chin, MD – Dell Medical School and Apricity Health LLC
Patricia Brown, JD – Medically Home Group
2:10–3:25 p.m. EST

2:10 p.m.

Precision in Care Delivery and Therapeutic Development in the Era of Digital Medicine
(View On-demand)
Sean Khozin, MD, MPH – CancerLinQ

2:15 p.m.

Bio/Pharma Perspective
(View On-demand)
Rasika Kalamegham, PhD – Genentech Roche

2:20 p.m.

Leveraging Digital Platforms to Achieve the Triple Aim
(View On-demand)
Patricia Brown, JD – Medically Home Group

2:25 p.m.

Creating a Learning Health Ecosystem to Connect Real-World Care and Discovery Research
(View On-demand)
Lynda Chin, MD – Dell Medical School and Apricity Health

2:30 p.m.

Panel Discussion
(View On-demand)

Concurrent Session 108: NK Cells
Location:
207
Co-Chairs: 
Lewis L. Lanier, PhD – University of California San Francisco
Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
2:10–3:25 p.m. EST

2:10 p.m.

Introduction
(View On-demand)
Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

2:15 p.m.

Natural Killer Cell Diversity and Activation
(View On-demand)
Lewis L. Lanier, PhD – University of California San Francisco

2:30 p.m.

Tumor Infiltrating NK Cells
(View On-demand)
Heidi Cerwenka – University of Heidelberg

2:45 p.m.

Adaptive NK Cells
(View On-demand)
Karl-Johan Malmberg, MD, PhD – Oslo University Hospital

3 p.m.

CRISPR-edited NK Cells
(View On-demand)
May Daher, MD – The University of Texas MD Anderson Cancer Center

3:15 p.m.

(216) Multiplex base editing of NK cell to enhance cancer immunotherapy
(View On-demand)
Minjing Wang, BSc – University of Minnesota

Concurrent Session 109: Biomarkers (Early Trials and Translational Research, Tissue Access Aspects)
Location:
Hall D
Co-Chairs:
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center
Alessandra Cesano, MD, PhD – ESSA Pharma Inc.
2:10–3:25 p.m. EST

2:10 p.m.

Introduction
(View On-demand)
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center

2:15 p.m.

Utility of the Circulating Tumor Genome in Informing Clinical Decisions-Immunotherapy and Combinations
(View On-demand)
Priti S. Hegde, PhD – Foundation Medicine

2:33 p.m.

Pronostic and Predictive Value of Tertiary Lymphoid Structures in Human Cancers
(View On-demand)
Catherine Sautes-Fridman, PHD – Centre de Recherche des Cordeliers

2:51 p.m.

Host Biomarkers (Microbiome)
Christine Spencer, PhD – Parker Institute for Cancer Immunotherapy

3:09 p.m.

(76) Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapy
(View On-demand)
Bryan Iorgulescu, MD – Dana-Farber Cancer Institute

Concurrent Session 110: Microbiome, Metabolism and ER Stress
Location:
East Salons
Co-Chairs:
Laurie H. Glimcher, MD – Dana-Farber Cancer Institute
Jennifer A. Wargo, MD, MMSc – The University of Texas MD Anderson Cancer Center
2:10–3:25 p.m. EST

Overview
(View On-demand)
Jennifer A. Wargo, MD, MMSc – The University of Texas MD Anderson Cancer Center

ER Stress
(View On-demand)
Juan R. Cubillos-Ruiz, PhD – Weill Cornell Medicine

Microbiome
Wendy Garrett, MD  – Harvard School of Public Health

Metabolic Impact on Tumor Immunity and Therapy
(View On-demand)
Weiping Zou, MD, PhD – University of Michigan

(839) Microbiota-specific T follicular helper cells drives tertiary lymphoid structure formation and anti-tumor immunity in colorectal cancer
(View On-demand)
Abigail Overacre-Delgoffe, PhD – University of Pittsburgh

(668) Lipid-instructed metabolic rewiring unleash the anti-tumor potential of CD8+ T cells
Teresa Manzo, PhD – IEO

Question and Answer
(View On-demand)

Concurrent Session 111: Intratumoral Therapy at a Crossroads
Location:
202AB
Co-Chairs: 
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Ichan School of Medicine at Mount Sinai
Adi Diab, MD – The University of Texas MD Anderson Cancer Center
2:10–3:25 p.m. EST

2:10 p.m.

Introduction
(View On-demand)
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Ichan School of Medicine at Mount Sinai

2:15 p.m.

State of the Field and Recent Trials
(View On-demand)
Adi Diab, MD – The University of Texas MD Anderson Cancer Center

2:25 p.m.

Standards for Intratumoral Therapies
(View On-demand)
Aurelien Marabelle, MD, PhD – Gustave Roussy

2:35 p.m.

Endpoints for Efficacy
(View On-demand)
Ignacio Melero, MD, PhD – FIMA, Clinica Universidad de Navarra

2:45 p.m.

Igniting the Fire: Intratumoral Therapy to Turn on Immune Response to Cancer
(View On-demand)
Antoni Ribas, MD, PhD – University of California Los Angeles

2:55 p.m.

Panel Discussion
(View On-demand)
Aurelien Marabelle, MD, PhD – Gustave Roussy
Ignacio Melero, MD, PhD – FIMA, Clinica Universidad de Navarra
Joshua Brody, MD – Ichan School of Medicine at Mount Sinai
Antoni Ribas, MD, PhD – University of California Los Angeles
Robert Andtbacka, MD, CM, FACS, FRCSC – Seven and Eight Biopharmaceuticals
Stephen Solomon, MD – Memorial Sloan Kettering Cancer Center
Craig L. Slingluff, MD – University of Virginia School of Medicine
Silvia Formenti, MD – Weill Cornell Medicine

Session 112: Debate: Engineered vs. Endogenous T cells
Location:
Hall D
Co-Chairs: 
Alex Marson, MD, PhD – University of California San Francisco
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center
3:25–4:35 p.m. EST

3:25 p.m.

Endogenous T cells
(View On-demand)
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

3:40 p.m.

Targeting Solid Malignancies with "Public" Neoantigen-Specific T Cells
Christopher A. Klebanoff, MD – Memorial Sloan Kettering Cancer Center

3:55 p.m.

Reprogramming T cell therapies with CRISPR
(View On-demand)
Alexander Marson, MD, PhD – University of California San Francisco

4:10 p.m.

Engineered T cells – Engineering Next Generation CAR-T Cells for Cancer
Yvonne Chen, PhD – University of California Los Angeles

4:25 p.m.

Panel Debate
Yvonne Chen, PhD – University of California Los Angeles
Christopher A. Klebanoff, MD – Memorial Sloan Kettering Cancer Center
Alexander Marson, MD, PhD – University of California San Francisco
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

4:35–4:50 p.m. EST

Break

Session 113: Debate: Declassification/deconvolution of T cell types
Location:
Hall D
Co-Chairs: 
Ira Mellman, PhD – Genentech, Inc.
Ansuman Satpathy, MD, PhD – Stanford
4:50–6 p.m. EST

4:50 p.m.

Introduction
(View On-demand)
Ansuman Satpathy, PhD – Stanford University

4:55 p.m.

Brief Summary – Exhaustion Side
(View On-demand)
E. John Wherry, PhD – University of Pennsylvania

5:05 p.m.

Brief Summary – Non-Exhausted Side
Andrea Schietinger, PhD – Memorial Sloan Kettering Cancer Center

5:15 p.m.

Panel Debate
E. John Wherry, PhD – University of Pennsylvania
Drew M. Pardoll, MD, PhD – Johns Hopkins University
Haydn Kissick, PhD – Emory University
Andrea Schietinger, PhD – Memorial Sloan Kettering Cancer Center

Session 114: Poster Symposium
Location:
Hall D
Co-Chairs:
Diwakar Davar, MD – UPMC Hillman Cancer Center
Amanda Lund, PhD – NYU Grossman School of Medicine
6–7 p.m. EST

6 p.m.

(30) Blood-based Glycoprotein Signatures in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Receiving First-Line Immune Checkpoint Blockade
(View On-demand)
Klaus Lindpaintner, MD, MPH – InterVenn

6:10 p.m

(748) Targeting vasoactive intestinal peptide receptor signaling in pancreatic ductal adenocarcinoma for enhanced anti-tumor response to checkpoint blockade
(View On-demand)
Sruthi Ravindranathan, PhD, MS – Emory University

6:20 p.m.

(663) Media based on the metabolic composition of tumor intersitial fluid reveals persistent T cell dysfunction induced through arginine deprivation and exposure to the oncometabolite phosphoethanolamine
Yupeng Wang, BS – University of Pittsburgh

6:30 p.m.

(683) Type-I-interfereon activates cross-dressed CD11b+ conventional dendritic cells to enhance anti-tumor immuity
Ellen Duong, ScB – Koch Institute

6:40 p.m.

(66) Prognostic and predictive value of pre-treatment T-Cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients with single agent immunotherapy
(View On-demand)
Afaf Abed, MBBS, FRACP – Edith Cowan University

6:50 p.m.

Question and Answer
(View On-demand)

7–8:30 p.m. EST

Poster Reception

Location:

Hall E

7 a.m.–8:30 p.m. EST

Poster and Exhibit Hall

Location:

Hall E

Session 200: SITC Business Meeting
Location:
Hall D
Chair:
Patrick Hwu, MD  – Moffitt Cancer Center
7:15–7:45 a.m. EST

Organizer Welcome
Location: 
Hall D
Chair:
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
8–8:05 a.m. EST

Awards Ceremony
8:05–8:20 a.m. EST
Location:
Hall D
Chair:
Leisha A. Emens, MD, PhD – UPMC Hillman Cancer Center

8:05 a.m.

Tara Withington Public Service

8:10 a.m.

Service to JITC

8:15 a.m.

2021 JITC Best Paper

Session 201: Update Session
8:20–9:05 a.m. EST
Location:
Hall D
Chair:
Leisha A. Emens, MD, PhD – UPMC Hillman Cancer Center

8:20 a.m.

Journal for ImmunoTherapy of Cancer (JITC) Update
(View On-demand)
Pedro J. Romero, MD – University of Lausanne & University Hospital of Lausanne

8:30 a.m.

National Cancer Institute (NCI) Update
(View On-demand)
Stephanie L. Goff, MD, FACS – National Cancer Institute Surgery Branch

8:45 a.m.

Remembrance of Drs. Martin 'Mac' Cheever and Thomas Waldmann
(View On-demand)
Patrick Hwu, MD – Moffitt Cancer Center
Philip D. Greenberg, MD – Fred Hutchinson Cancer Center
Carol Waldmann, MD

Session 202: Richard V. Smalley Memorial Award and Lectureship
Location:
Hall D
Chair:
Patrick Hwu, MD – Moffitt Cancer Center
9:05–9:55  a.m. EST

9:05 a.m.

Introduction & 2021 Richard V. Smalley Memorial Award and Lectureship Recognition
(View On-demand)
Patrick Hwu, MD – Moffitt Cancer Center

9:10 a.m.

CAR-T Cells for Solid Tumors: Charting a Path Forward
(View On-demand)
Crystal Mackall, MD – Stanford University

9:50 a.m.

9:55 – 10:10 a.m.

Break

Session 203: COVID Immunobiology/Immunology
Location:
Hall D
Co-Chairs: 
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
Kizzmekia Corbett, PhD – National Institutes of Allergy and Infectious Diseases, NIH
10:10 a.m.–Noon EST

10:10 a.m.

Opening Remarks
(View On-demand)
Kizzmekia Corbett, PhD – National Institutes of Allergy and Infectious Diseases, NIH

10:15 a.m.

Immune Memory to COVID-19 Infection
(View On-demand)
Rafi Ahmed, PhD –Emory University

10:37 a.m.

Immune responses to SARS-COV2 vaccination in Multiple Myeloma
(View On-demand)
Samir Parekh, MD – Mount Sinai School of Medicine

10:59 a.m.

T-cell Responses to COVID-19
(View On-demand)
Alesandrao Sette, MD – La Jolla Institute for Immunology

11:21 a.m.

(625) COVID-19 vaccination in patients with renal cancer or melanoma receiving immune checkpoint inhibitors
(View On-demand)
Hannah E. Dzimitrowicz, MD – Duke Cancer Center

11:38 a.m.

(626) Dissecting the spatial heterogeneity of SARS-CoV-2-infected tumour microenvironment reveals a lymphocyte-dominant immune response in a HBV-associated HCC patient with COVID-19 history
(View On-demand)
Mai Chan Lau, PhD – Institute of Molecular and Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR)

11:55 a.m.

Closing Remarks
(View On-demand)

Session 204: Late-Breaking Abstract Session
Location:
Hall D
Chair:
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine
Noon–12:30 p.m. EST

Noon

(959) Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial
Martin Wermke – Uniklinikum Dresden

12:15 p.m.

(955) CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
(View On-demand)
Roger Li, MD – Moffitt Cancer Center

12:30–2 p.m. EST

Lunch and Poster Viewing

Location:

Hall E

Concurrent Rapid Oral Abstract Presentation Session 205: Basic Research
Location:
West Salons
Co-Chairs:
Kristin G. Anderson, PhD – Fred Hutchinson Cancer Research Center
Olivia Rongze Lu, PhD – University of Texas at Austin, Dell Medical School
12:45–1:45 p.m. EST

(43) Intravital multiphoton imaging of infiltrating CD8 T cell metabolism during immunotherapy in a murine melanoma model
(View On-demand)
Alexa R. Heaton, PhD – Morgridge Institute of Research, University of Wisconsin

(658) CD8 T cell activation in cancer is comprised of two distinct phases
(View On-demand)
Nataliya Prokhnevska, BS – Emory University

(660) Targeting T cell fates: converting exhaustion to memory to improve immunotherapeutic responses to cancer
(View On-demand)
Nicole E. Scharping, PhD – University of California San Diego

Question and Answer
(View On-demand)

(936) Stromal remodeling regulates dendritic cell abundance in the tumor microenvironment
Athanasios Papadas, MD, PhD – University of California San Diego

(601) Sequencing Immunotherapy Before Lymphatic Ablation Unleashes cDC1-Dependent Antitumor Immunity in HNSCC
(View On-demand)
Robert Saddawi-Konefka, MD, PhD – University of California San Diego School of Medicine

(125) Co-opting IL-8 to enhance efficacy of B7H3 CAR T cells against pediatric sarcoma
(View On-demand)
Jessica Lake, MD, MPH – University of Colorado Anschutz Medical Campus

Question and Answer
(View On-demand)

Concurrent Rapid Oral Abstract Presentation Session 206: Clinical
Location:
East Salons
Co-Chairs:
Praveen Bommareddy, MS, PhD – Replimune Inc.
Chris Langsdorf – Thermo Fisher Scientific
12:45–1:45 p.m. EST

(493) First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40x4-1BB (GEN1042) in patients with advanced solid tumors
(View On-demand)
Melissa L. Johnson, MD – Sarah Cannon Research Institute

(350) Phase 2 trial of a DNA vaccine with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
(View On-demand)
Douglas G. McNeel, MD, PhD – Carbone Cancer Center, University of Wisconsin

(449) Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with liscabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy
(View On-demand)
Jerill Thorpe, MS – Bristol Myers Squibb

Question and Answer
(View On-demand)

(374) A Phase IB trial of ziv-afilibercept plus pembrolizumab in patients with advanced solid tumors
(View On-demand)
Kevin Tyan, BA – Harvard Medical School

(529) Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors
Eric Van Cutsem, MD, PhD – University Hospital Gathiusberg Leuven

(490) Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors
(View On-demand)
Elaine Shum, MD – New York University Langone Health

Question and Answer
(View On-demand)

Session 207: Presidential Session
Location:
Hall D
Chair: 
Patrick Hwu, MD – Moffitt Cancer Center
2–3:25 p.m. EST

2:00 p.m.

Introduction
(View On-demand)
Patrick Hwu, MD – Moffitt Cancer Center

2:05 p.m.

(592) ATR-mediated CD47 and PD-L1 upregulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer
Rodney Cheng-En Hsieh, MD – The University of Texas MD Anderson Cancer Center

2:20 p.m.

(900) Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner
(View On-demand)
Anand V. Kornepati – University of Texas Health Science Center San Antonio

2:35 p.m.

Expert Discussant
(View On-demand)
Sandra Demaria, MD – Weill Cornell Medicine

2:45 p.m.

(152) Common trajectories of highly effective anti-CD19 chimeric antigen receptor-modified T cells identified by endogenous T cell receptor lineages
(View On-demand)
Taylor L. Wilson, BS – St. Jude Children's Research Hospital

3:00 p.m.

(328) Batf3 dendritic cells and 4-1BB/4-1BB ligand axis are required at the effector phase within tumor microenvironment for anti0PD-L1 efficacy
(View On-demand)
Andrea Ziblat, PhD – University of Chicago

3:15 p.m.

Expert Discussant
(View On-demand)
E. John Wherry, PhD – University of Pennsylvania

3:25–3:40 p.m. EST

Break

Concurrent Session 208: Locoregional Therapies, Including Radiation, Oncolytic Viruses and Innate Immune Modulators
Location:
West Salons
Co-Chairs: 
James W. Welsh, MD – The University of Texas MD Anderson Cancer Center
Dimitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center
3:40–4:55 p.m. EST

3:40 p.m.

Using Low Dose Radiation and Nanoparticles to address PD1 Resistance
(View On-demand)
James W. Welsh, MD – The University of Texas MD Anderson Cancer Center

4 p.m.

Modulation of Anti-Tumor Immunity with Oncolytic Viruses
Dimitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

4:20 p.m.

Modulators of Tumor Antigenicity by Radiation Therapy
Nils Rudqvist, PhD – The University of Texas MD Anderson Cancer Center

4:30 p.m.

(768) Systemic delivery of a tumor-targeted TLR9 agonist conjugate transforms the tumor immune landscape and induces tumor regression in mice
(View On-demand)
Caitlyn Miller, PhD Candidate – Stanford University

4:40 p.m.

(758) High-potency synthetic STING agonists rewire the myeloid stroma in the tumor microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma
(View On-demand)
Akash R. Boda, MS – The University of Texas MD Anderson Cancer Center

4:50 p.m.

Questions
(View On-demand)

Concurrent Session 209: Single Cell Approaches to Advancing Understanding of Immunotherapy Resistance
Location:
202AB
Co-Chairs:
Kellie N. Smith, PhD – Johns Hopkins School of Medicine
Daniel K. Wells, PhD – Parker Institute for Cancer Immunotherapy
3:40–4:55  p.m. EST

3:40 p.m.

Introduction
(View On-demand)
Kellie N. Smith, PhD – Johns Hopkins School of Medicine

3:45 p.m.

Keynote
(View On-demand)
Ansuman Satpathy, MD, PhD – Stanford University School of Medicine

4:10 p.m.

Longitudinal Single Cell Genomics Reveals Mechanisms of Resistance to Combination Immune Checkpoint Blockade
(View On-demand)
Alexander Huang, MD – University of Pennsylvania

4:20 p.m.

Increased Post-Infusion CD57+ CD19-CAR T Cells in Patients with Durable Remission
(View On-demand)
Zinaida Good, PhD – Stanford University

4:30 p.m.

Epigenomic Features of Exhausted T-cells During Immunotherapy
Debattama Sen, PhD – Massachusetts General

4:40 p.m.

(655) Landscape of helper and regulatory CD4+ T cells in melanoma
Giacomo Oliveira, PhD – Dana-Farber Cancer Institute

4:50 p.m.

Closing Remarks
(View On-demand)
Daniel K. Wells, PhD – Parker Institute for Cancer Immunotherapy

Concurrent Session 210: Novel Targets, Resistance Mechanisms
Location:
Hall D
Co-Chairs: 
Jason J. Luke, MD, FACP – UPMC
Irving L. Weissman, MD – Stanford University
3:40–4:55 p.m. EST

3:40 p.m.

Targeting Glycobiology as a Therapeutic Approach in Cancer Immunotherapy
(View On-demand)
Carolyn Bertozzi, PhD – Stanford University

3:55 p.m.

Normal and Neoplastic Stem Cells
(View On-demand)
Irving L. Weissman, MD – Stanford University

4:10 p.m.

Moving Beyond First Generation STING Agonist Approaches
(View On-demand)
Jason J. Luke, MD, FACP – UPMC Hillman Cancer Center

4:25 p.m.

Flanking Solid Tumors via Immune-Mediated Disruption of Desmoplastic Stroma
(View On-demand)
Ellen Pure, PhD – University of Pennsylvania

4:40 p.m.

(261) A functional genetic screen uncovers regulators of intratumoral macrophages function and reveals CD24 as a novel target for cancer immunotherapy by macrophages
(View On-demand)
Amira Barkal, MD, PhD – Brigham & Women's Hospital

Concurrent Session 211: Team Science to Catalyze Advancements in Research
Location:
207
Co-Chairs: 
Luis A. Diaz, MD – Memorial Sloan Kettering Cancer Center
Mark Stewart, PhD – Friends of Cancer Research
3:40–4:55 p.m. EST

3:40 p.m.

TMB in immunotherapy: is the hype justified?
Luc Morris, MD – Memorial Sloan Kettering Cancer Center

3:55 p.m.

High TMB Fails to Predict Immune Checkpoint Blockade Response in All Cancer Types
(View On-demand)
Daniel J. McGrail, PhD – The University of Texas MD Anderson Cancer Center

4:10 p.m.

KN158 TMB Data
(View On-demand)
Aurelien Marabelle, MD, PhD – Gustave Roussy

4:25 p.m.

UVB-induced Tumor Heterogeneity Directs Immune Response in Melanoma
(View On-demand)
Yardena Samuels, PhD – Weizmann Institute of Science

4:40 p.m.

Panel Discussion
Aurelien Marabelle, MD, PhD – Gustave Roussy
Daniel J. McGrail, PhD – The University of Texas MD Anderson Cancer Center
Luc Morris, MD – Memorial Sloan Kettering Cancer Center
Eric Rubin, MD – Merck
Yardena Samuels, PhD – Weizmann Institute of Science

Concurrent Session 212: Cellular Therapies
Location:
East Salons
Co-Chairs: 
Michel Sadelain, MD, PhD – Memorial Sloan Kettering Cancer Center
Philip D. Greenberg, MD – Fred Hutchinson Cancer Center
3:40–4:55 p.m. EST

3:40 p.m.

(561) Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer
(View On-demand)
Kristin G. Anderson, PhD – Fred Hutchinson Cancer Center

3:55 p.m.

(578) CD8-targeting IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines
Robert D. Schreiber, PhD –  Washington University School of Medicine

4:10 p.m.

(117) FT536 Path to IND: Ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy
(View On-demand)
Bryan Hancock, PhD – Fate Therapeutics

4:25 p.m.

(221) CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors
Rebecca C. Larson, BS – Jounce Therapeutics

4:40 p.m.

(132) HLA-independent T cell receptors effectively target low abundance antigens
Jorge Mansilla-Soto, PhD – Memorial Sloan Kettering Cancer Center

Concurrent Session 213: A Multidisciplinary Approach to Neoadjuvant, Intralesional, and Cell-based Immunotherapy
Location:
204ABC
Co-Chairs: 
Genevieve Boland, MD, PhD – Massachusetts General Hospital
Kelly Olino, MD, FACS – Yale School of Medicine
3:40–4:55 p.m. EST

4:55–5:10 p.m. EST

Break

Concurrent Session 214: Radiomics & Imaging
Location:
202AB
Co-Chairs: 
Neeta Pandit-Taskar, MD – Memorial Sloan Kettering Cancer Center
Ian A. Wilson, PhD – ImaginAb Inc.
5:10–6:25 p.m. EST

 5:10 p.m.

CT Radiomics in Immuno-Oncology Clinical Development for Lung Cancer
(View On-demand)
Qin Li, MD, PhD – AstraZeneca

 5:35 p.m.

 6:00 p.m.

Cell Labelling Methods to Track Immune Cells
(View On-demand)
Peter Choyke, MD –  National Institutes of Health

Concurrent Session 215: Clinical Considerations for Toxicity Management and Survivorship
Location:
207
Co-Chairs: 
Marc S. Ernstoff, MD – National Institute of Health
Mary-Kate Kasler, DNP – Memorial Sloan Kettering Cancer Center
5:10–6:25 p.m. EST

5:10 p.m.

Clinical Considerations for Immune Checkpoint Inhibitor Toxicity Management and Survivorship
(View On-demand)
Marianne Davies, DNP, AOCNP – Yale School of Nursing

5:30 p.m.

Survivorship & Toxicity Management – Physician Perspective
(View On-demand)
Jarushka Naidoo, MBBCH, MHS – Beaumont Hospital Dublin

5:50 p.m.

(234) Distinct efficacy and immunological responses to to αPD-1, ⍺PD-L1 and ⍺PD-L2 immunotherapy in aged versus young hosts
(View On-demand)
Myrna G. Garcia, BS – UTHSA

6 p.m.

(806) PD-1 blockade affects inflammation and metabolic flexibility to potentially mediate cardiac immune-related adverse events
Steven M. Bronson, DVM – Wake Forest School of Medicine

6:10 p.m.

(814) Cutaneous Immune-related Adverse Events are Protective of Mortality in Patients Treated with anti-PD1 and anti-PDL1 therapy in a multi-institutional cohort study
(View On-demand)
Yevgeniy R. Semenov, MD – Massachusetts General Hospital, Harvard Medical School

6:20 p.m.

Expert Discussant
(View On-demand)
Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center

Concurrent Session 216: Exosomes and Cellular Engineering
Location:
West Salons
Co-Chairs:
Sriram Sathyanarayanan, PhD – Codiak BioScience
Helen E. Heslop, MD – Baylor College of Medicine
5:10–6:25 p.m. EST